Balixafortide (a novel CXCR4 inhibitor) and eribulin in HER2-neg metastatic breast cancer (MBC) patients (pts): A phase I trial

  1. Cortes Castan, J.
  2. Martín, M.
  3. Pernas Simon, S.
  4. Gomez Pardo, P.
  5. Lopez-Tarruella, S.
  6. Gil Martin, M.
  7. Manso, L.M.
  8. Ciruelos, E.M.
  9. Perez Fidalgo, J.A.
  10. Hernando, C.
  11. Ademuyiwa, F.
  12. Weilbaecher, K.
  13. Mayer, I.A.
  14. Pluard, T.
  15. Martinez Garcia, M.
  16. Vahdat, L.T.
  17. Wach, A.
  18. Barker, D.
  19. Romagnoli, B.
  20. Kaufman, P.A.
Revue:
Annals of oncology : official journal of the European Society for Medical Oncology

ISSN: 1569-8041

Année de publication: 2018

Volumen: 29

Pages: viii91-viii92

Type: Article

DOI: 10.1093/ANNONC/MDY272.277 GOOGLE SCHOLAR lock_openAccès ouvert editor

Objectifs de Développement Durable

La source de données: Scopus